Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
By M. Gilbert, Meihua Wang, Kenneth D. Aldape, R. Stupp, M. Hegi, K. Jaeckle, T. Armstrong, J. Wefel, M. Won, D. Blumenthal and 10 more. Journal of Clinical Oncology, 2013
928 citations recorded by the source corpus.
Subfields: Genetics, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/1e47f5f9a3ed001cda40d1e0c716d622b8ce28d7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Oncology
Citations in the corpus
- Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. (2015, methodology): “Duration of treatment with TTFields, median (range), mo 9 (1-58) 9 (1-58)”
- Immunotherapy for glioma: current management and future application. (2020, neutral): “In addition, O-6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation has been found to be a strong prognostic factor in patients with GBM [8].”
- Identifying the Best Machine Learning Algorithms for Brain Tumor Segmentation, Progression Assessment, and Overall Survival Prediction in the BRATS Challenge (2018, background): “The median OS of the described cohorts is not significantly different from the median OS of GBM patients in several randomized Phase III trials, noting that our cohort consists of unselected patients rather than those eligible for such trials [13,14].”
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial (2017, neutral): “0 (70-100) 90-100 308 (66) 149 (65) ≤80 154 (33) 74 (32) Missing 4 (1) 6 (3) Sex Men 316 (68) 157 (69) Women 150 (32) 72 (31) Region United States 221 (47) 118 (52) Outside the United States 245 (53) 111 (48) Race/ethnicity White 416 (89) 201 (88) African American 3 (1) 1 (<1) Asian 27 (6) 19 (8) Hi”
- High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “Concomitant and adjuvant TMZ chemotherapy in addition to radiotherapy (TMZ/RT→ TMZ) significantly improved median, 2- and 5-year survival in a large randomised trial, and is the current standard of care for patients with GBM up to age 70 [34, 35] [I, A], or fit elderly patients older than 70 years [”